The two main hypotheses being tested in TriMaster
obesity
OBESITY
Trial profile (CONSORT diagram): patient flow through the stages of the crossover trial and eligibility for primary analysis. Numbers presented for each visit are the numbers assigned each drug at that time. For an HbA1c to be valid for primary analysis, it needed to be taken after at least 12 weeks of therapy (exclusions indicated by <12wks), and participants needed to have at least 80% adherence on the therapy (exclusions indicated by adh<80%). P= pioglitazone, S=sitagliptin, C=canagliflozinEffect of stratification on treatment response. Point estimates represent the mean difference in HbA1c between the two therapies for a) hypothesis 1 - pioglitazone and sitagliptin, with stratification by obesity (n=141 BMI<=30; n=215 BMI >30), and b) hypothesis 2 – canagliflozin and sitagliptin, with stratification by renal function (eGFR) (n=163 eGFR 60-90; n=179 eGFR>90). Error bars represent 95% confidence intervals. Overall difference between strata determined from drug*strata interaction in mixed effects analysis adjusting for period.